

Improve accuracy of VTE prophylaxis by strict guideline application

Amanda Lu MD/PhD, Boniface Malangu MD, Vanessa Browne MD, Ana Diaz MD, Dhvani Doshi MD, Mirela Feurdean MD Internal Medicine Department, Rutgers - New Jersey Medical School, Newark, NJ 07103

Background

Hospital-acquired venous thromboembolism (VTE) occurs at significant rates. 50% of these are preventable with appropriate pharmacological and/or mechanical prophylaxis. Pharmacological prophylaxis (PP) using low molecular weight heparin (LMWH), and unfractionated heparin (UH), are regulated by society and hospital guidelines, which should be followed for standard of care in order to prevent the occurrence of hospital acquired venous thromboembolism. This quality improvement project aimed to investigate whether PP was prescribed based on updated society and hospital guidelines.

Purpose


This quality improvement project aimed to investigate whether PP was prescribed based on updated society and hospital guidelines.

Methods


Patient demographic data (age, gender, height, weight) affecting guideline factors (renal function, active bleeding, applications current anticoagulant use, malignancy, COVID status) were collected and investigated from 100 consecutive patients on the medical/surgical floor at UH.

Kahn, S. R, et al. (2012). Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical


UH VTE Prophylaxis Flowchart



Are We Following the Guidelines?



Factors Affecting Guidelines Applications



Results

A total of 100 consecutive patients, 53 males and 47 females, ages ranging 25 to 93 years, who were admitted to UH in April 2021, were included in the study through a cross-sectional chart review. We found that anticoagulants were correctly ordered in 70% of the patients based on society and/or hospital guidelines. Further study showed incorrect AC was ordered in 17 (CrCl, P <0.05; COVID severity, P < 0.05; BMI, P > 0.05; religion, P > 0.05) and no AC was ordered in 13 when indicated (P < 0.05). Guidelines are applied more accurately in patients with current AC use, active bleeding, long bone fracture, and malignancy.

Conclusions

VTE prophylaxis with correct formula and dose is effective at preventing avoidable death, disability, and chronic ill health in at-risk hospitalized medical patients. There is room for improvement in following standard of care at UH while prescribing AC for VTE prophylaxis in hospitalized patients. Increased awareness and special attention should be paid to CrCl, COVID severity, BMI to improve the accuracy by strict guideline application, thus enhancing patient safety and standard of care.

Aloia, T. A., et al (2016). Venous thromboembolism prophylaxis in liver surgery. Journal of Gastrointestinal Surgery, 20(1), 221-229.

Falck-Ytter, Y., et al. (2012). Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2), e278S-e325S. Geerts, W. H., et al. (2008). Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. Chest Journal, 133(6_suppl), 381S-453S. Gould, M. K., et al. (2012). Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based

Leonardi, M. J., et al (2006). The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: A systematic review of 33 randomized controlled trials. Archives of

clinical practice guidelines. CHEST Journal, 141(2_suppl), e227S-e277S.

practice guidelines. Chest, 141(2), e195S-e226S. doi:10.1378/chest.11-2296 National Comprehensive Cancer Network. (2020). Cancer-Associated Venous Thromboembolic Disease. (NCCN Guideline - Version 1.2020). Scholten, D. J., et al. (2002). A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obesity Surgery, 12(1), 19-24.

Sebaaly, J., et al. (2018). Enoxaparin dosing at extremes of weight: Literature review and dosing recommendations. Annals of Pharmacotherapy, 52(9), 898-909.

Yam, L., et al. (2019). Enoxaparin Thromboprophylaxis Dosing and Anti–Factor Xa Levels in Low-Weight Patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 39(7), 749-755.